The trial will evaluate the efficacy and safety of belzupacap sarotalocan (bel-sar) with suprachoroidal administration, for the first-line treatment of early-stage choroidal melanoma (CM).
Leer más
Minoryx Therapeutics, compañía biotecnológica en fase avanzada especializada en el desarrollo de tratamientos para enfermedades raras del sistema nervioso central (SNC) y el Grupo Neuraxpharm («Ne...
Leer más
Kala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported...
Leer más
Galecto, Inc., a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced it will discuss topline d...
Leer más
New innovations, like AELIX’ T-cell vaccine, leading to a prolonged period without ART, could be a gamechanger in HIV cure strategies as a combination approach to treating the disease.
Leer más
Clear path forward for ilofotase alfa as potential treatment in acute kidney injury, based on consistent improvement of renal parameters observed in REVIVAL and other clinical studies
Leer más
Xeltis, a medtech company developing the most advanced polymer-based restorative cardiovascular devices, today announced very promising preliminary efficacy and safety results from one of the centers ...
Leer más
Aura Biosciences today announced the first patient has been dosed in a Phase 1 study evaluating belzupacap sarotalocan, the Company’s first VDC product candidate, for the treatment of Non-Muscle Inv...
Leer más
Galecto today announced positive results from a planned intermediate assessment of its ongoing Phase 2a trial of GB2064 for the treatment of myelofibrosis
Leer más
Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vγ9Vδ2 (Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid Tumors
Leer más
SparingVision (“the Company”), a genomic medicine company developing vision-saving treatments for ocular diseases, today announces that it has raised €75 million in a Series B financing. The rou...
Leer más
Equity and licensing investment for aXess device marks first commercial deal
Leer más
El equipo de investigadores observó cambios en el...
El gen AtCDF3 promueve una mayor producción de az...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del si...
Los investigadores han confirmado que las pacientes con presencia de l...
